Rapid hemodilution induced by desmopressin after erythropoietin administration in humans
DOI:
https://doi.org/10.4100/jhse.2011.62.12Keywords:
Haemoglobin, Haematocrit, Reticulocytes, Stimulation index and plasma volume expandersAbstract
We have shown that treatment with desmopressin has a very effective hemodilution effect in healthy humans. These results led us to suggest the possible role of desmopressin to mask blood doping in sports. Based on our results, the World Anti-Doping Agency included the desmopressin in the 2011 List of Prohibited Substances and Methods. On this occasion, the aim of our study was to test the desmopressin-induced hemodilution after rHuEpo administration in humans. This was an intra-subject, crossover study in which five physically active males acted as their own controls. A basal blood sample was taken on their first visit to the laboratory. The next day, the subjects began the treatment. They received a subcutaneous rHuEpo injection three times/week for a two-week period. On the second visit to the laboratory, seventeen days later, a blood sample was taken. Thereafter, the subjects received an oral dose of 4.3 μg/kg of desmopressin and were instructed to ingest 1.5 liters of mineral water during the following fifteen minutes. Three hours after the water ingestion a second blood sample was obtained. The samples were analyzed for hematocrit (HCT), hemoglobin (Hb), reticulocytes (Ret%) and OFF Hr-Score. We found significantly higher HCT, Hb and Ret% levels after rHuEpo administration. Administration of desmopressin significantly decreased the HCT and Hb values but we did not find significant changes in Ret%. The values of the OFF Hr-Score also decreased after treatment with desmopressin. Desmopressin has a very effective hemodilution effect after rHuEpo administration and significantly modifies the hematological values measured by the anti-doping authorities to detect blood doping. We consider that these results reinforce the conclusions reported in our first study and confirm that desmopressin is a very effective masking agent for blood doping.
Downloads
References
Ashenden, M., Gough, C.E., Garnham, A., Gore, C.J., Sharpe, K. Current markers of the Athlete Blood Passport do not flag microdose EPO doping. Eur J Appl Physiol. 2011. https://doi.org/10.1007/s00421-011-1867-6
Audran, M., Gareau, R., Matecki, S., Durand, F., Chenard, C., Sicart, M.T., Marion, B., Bressolle, F. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc. 1999; 31:639-645. https://doi.org/10.1097/00005768-199905000-00003
Berger, N.J., Campbell, I.T., Wilkerson, D.P., Jones, A.M. Influence of acute plasma volume expansion on VO2 kinetics, VO2 peak, and performance during high-intensity cycle exercise. J Appl Physiol. 2006; 101:707-714. https://doi.org/10.1152/japplphysiol.00154.2006
Brien, A.J., Simon, T.L. The effects of red blood cell infusion on 10-km race time. Jama. 1987; 257:2761-2765. https://doi.org/10.1001/jama.1987.03390200101022
Cooper, C.E., Beneke, R. Drugs and Ergogenic Aids to Improve Sport Performance. London: Portland Press; 2008.
Damsgaard, R., Munch, T., Morkeberg, J., Mortensen, S.P., Gonzalez-Alonso, J. Effects of blood withdrawal and reinfusion on biomarkers of erythropoiesis in humans: Implications for anti-doping strategies. Haematologica. 2006; 91:1006-1008.
Dimson, S.B. Desmopressin as a treatment for enuresis. Lancet. 1977; 1:1260. https://doi.org/10.1016/S0140-6736(77)92467-9
Ekblom, B., Wilson, G., Astrand, P.O. Central circulation during exercise after venesection and reinfusion of red blood cells. J Appl Physiol. 1976; 40:379-383.
Gilbert, S. The biological passport. Hastings Cent Rep. 2010; 40:18-19. https://doi.org/10.1353/hcr.0.0235
Gore, C.J., Parisotto, R., Ashenden, M.J., Stray-Gundersen, J., Sharpe, K., Hopkins, W., Emslie, K.R., Howe, C., Trout, G.J., Kazlauskas, R., Hahn, A.G. Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica. 2003; 88:333-344.
Guddat, S., Thevis, M., Schanzer, W. Identification and quantification of the plasma volume expander dextran in human urine by liquid chromatography-tandem mass spectrometry of enzymatically derived isomaltose. Biomed Chromatogr. 2005; 19:743-750. https://doi.org/10.1002/bmc.509
Guddat, S., Thevis, M., Thomas, A., Schanzer, W. Rapid screening of polysaccharide-based plasma volume expanders dextran and hydroxyethyl starch in human urine by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2008; 22:695-701. https://doi.org/10.1002/bmc.986
Kim, R.J., Malattia, C., Allen, M., Moshang, T., Jr., Maghnie, M. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations. Pediatr Endocrinol Rev. 2004; 2(1):115-123.
Lasne, F. Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in immunoblotting procedures. J Immunol Methods. 2001; 253:125-131. https://doi.org/10.1016/S0022-1759(01)00355-6
Levy, J.H. Pharmacologic methods to reduce perioperative bleeding. Transfusion. 2008; 48:31S-38S. https://doi.org/10.1111/j.1537-2995.2007.01574.x
Morkeberg, J., Belhage, B., Ashenden, M., Borno, A., Sharpe, K., Dziegiel, M.H., Damsgaard, R. Screening for autologous blood transfusions. Int J Sports Med. 2009a; 30:285-292. https://doi.org/10.1055/s-0028-1105938
Morkeberg, J., Sharpe, K., Belhage, B., Damsgaard, R., Schmidt, W., Prommer, N., Gore, C.J., Ashenden, M.J. Detecting autologous blood transfusions: a comparison of three passport approaches and four blood markers. Scand J Med Sci Sports. 2009b. https://doi.org/10.1111/j.1600-0838.2009.01033.x
Parisotto, R., Ashenden, M.J., Gore, C.J., Sharpe, K., Hopkins, W., Hahn, A.G. The effect of common hematologic abnormalities on the ability of blood models to detect erythropoietin abuse by athletes. Haematologica. 2003; 88:931-940.
Parisotto, R., Wu, M., Ashenden, M.J., Emslie, K.R., Gore, C.J., Howe, C., Kazlauskas, R., Sharpe, K., Trout, G.J., Xie, M. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica. 2001; 86:128-137.
Robinson, A.G. DDAVP in the treatment of central diabetes insipidus. N Engl J Med. 1976; 294:507-511. https://doi.org/10.1056/NEJM197603042941001
Sanchis-Gomar, F., Martinez-Bello, V.E., Gomez-Cabrera, M.C., Vina, J. The hybrid algorithm (Hbmr) to fight against blood doping in sports. Scand J Med Sci Sports. 2010a; 20:789-79. https://doi.org/10.1111/j.1600-0838.2010.01224.x
Sanchis-Gomar, F., Martinez-Bello, V.E., Nascimento, A.L., Perez-Quilis, C., Garcia-Gimenez, J.L., Vina, J., Gomez-Cabrera, M.C. Desmopressin and hemodilution: implications in doping. Int J Sports Med. 2010b; 31:5-9. https://doi.org/10.1055/s-0029-1239500
Sharpe, K., Ashenden, M.J., Schumacher, Y.O. A third generation approach to detect erythropoietin abuse in athletes. Haematologica. 2006; 91:356-363.
Thevis, M., Opfermann, G., Schanzer, W. Detection of the plasma volume expander hydroxyethyl starch in human urine. J Chromatogr B Biomed Sci Appl. 2000; 744:345-350. https://doi.org/10.1016/S0378-4347(00)00251-6
Ventura, R., Segura, J. Masking and manipulation. Handb Exp Pharmacol. 2010; 327-354. https://doi.org/10.1007/978-3-540-79088-4_15
WADA. The 2011 prohibited list of Substances international standard. www.wada-ama.org. 2011; 1-11.
Zorzoli, M., Rossi, F. Implementation of the biological passport: the experience of the International Cycling Union. Drug Test Anal. 2010; 2:542-547. https://doi.org/10.1002/dta.173
Downloads
Statistics
How to Cite
Issue
Section
License
Copyright (c) 2011 Journal of Human Sport and Exercise
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Each author warrants that his or her submission to the Work is original and that he or she has full power to enter into this agreement. Neither this Work nor a similar work has been published elsewhere in any language nor shall be submitted for publication elsewhere while under consideration by JHSE. Each author also accepts that the JHSE will not be held legally responsible for any claims of compensation.
Authors wishing to include figures or text passages that have already been published elsewhere are required to obtain permission from the copyright holder(s) and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Please include at the end of the acknowledgements a declaration that the experiments comply with the current laws of the country in which they were performed. The editors reserve the right to reject manuscripts that do not comply with the abovementioned requirements. The author(s) will be held responsible for false statements or failure to fulfill the above-mentioned requirements.
This title is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license (CC BY-NC-ND 4.0).
You are free to share, copy and redistribute the material in any medium or format. The licensor cannot revoke these freedoms as long as you follow the license terms under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
Transfer of Copyright
In consideration of JHSE’s publication of the Work, the authors hereby transfer, assign, and otherwise convey all copyright ownership worldwide, in all languages, and in all forms of media now or hereafter known, including electronic media such as CD-ROM, Internet, and Intranet, to JHSE. If JHSE should decide for any reason not to publish an author’s submission to the Work, JHSE shall give prompt notice of its decision to the corresponding author, this agreement shall terminate, and neither the author nor JHSE shall be under any further liability or obligation.
Each author certifies that he or she has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article, except as disclosed on a separate attachment. All funding sources supporting the Work and all institutional or corporate affiliations of the authors are acknowledged in a footnote in the Work.
Each author certifies that his or her institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research.
Competing Interests
Biomedical journals typically require authors and reviewers to declare if they have any competing interests with regard to their research.
JHSE require authors to agree to Copyright Notice as part of the submission process.
